Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut
- Address
- Gerhard-Ellrodt-Str. 19, 04249 Leipzig, Germany
Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut - Metabolic and Gastrointestinal Research Center
Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut is a clinical research practice specializing in metabolic disorders and gastrointestinal health. The center demonstrates particular expertise in evaluating novel therapeutic approaches for Type 2 Diabetes, obesity management, and functional digestive disorders, with a strong focus on cardiovascular risk reduction in metabolic populations.
- Type 2 Diabetes management and glycemic control optimization studies, including combination therapies with GLP-1 receptor agonists
- Obesity and overweight treatment research with focus on weight-related comorbidities and cardiovascular risk factors
- Functional gastrointestinal disorders including assessment of herbal therapeutic agents and gut permeability parameters
The practice participates in comprehensive clinical trials ranging from master protocol studies evaluating oral GLP-1 receptor agonists to investigations of natural product therapies for digestive health. Their research portfolio emphasizes patient-centered outcomes including quality of life assessments, treatment satisfaction, and long-term safety monitoring. The center's involvement in cardiovascular outcome trials demonstrates commitment to evaluating treatments that address the complex interplay between metabolic disorders and cardiovascular disease risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Eli Lilly & Co.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Orforglipron in Obesity or Overweight Patients With and Without Type 2 Diabetes: A Master Protocol Study | Eli Lilly & Co. | Phase III | Not Recruiting | Aug 2025 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Canagliflozin | 1 | Unknown | 2023-08-02 | 2023-08-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.